List of OncoImmune patents

List of OncoImmune patents

List of Fitbit patents

List of ESCO Corporation patents

List of Vuereal Inc. patents

List of Blue Startups Cohort 5 companies

Strategic partnerships in technology

Patents where

Current Assignee

Name

is

OncoImmune

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 9877998 Uses of hypoxia-inducible factor inhibitors	Patent 9877998 was granted and assigned to OncoImmune on January, 2018 by the United States Patent and Trademark Office.	OncoImmune	OncoImmune		United States Patent and Trademark Office	9877998	January 30, 2018
	‌ US Patent 11571461 Methods of use of soluble CD24 for treating lupus nephritis	Patent 11571461 was granted and assigned to OncoImmune on February, 2023 by the United States Patent and Trademark Office.	OncoImmune	OncoImmune		United States Patent and Trademark Office	11571461	February 7, 2023
	‌ US Patent 10369197 Use of CD24 for lowering low-density lipoprotein cholesterol levels	Patent 10369197 was granted and assigned to OncoImmune on August, 2019 by the United States Patent and Trademark Office.	‌ Oncolmmune	OncoImmune		United States Patent and Trademark Office	10369197	August 6, 2019
	‌ US Patent 8895022 Methods of use of soluble CD24 for therapy of rheumatoid arthritis		OncoImmune	OncoImmune		United States Patent and Trademark Office	8895022	November 25, 2014
	‌ US Patent 9427413 Uses of hypoxia-inducible factor inhibitors	Patent 9427413 was granted and assigned to OncoImmune on August, 2016 by the United States Patent and Trademark Office.		OncoImmune		United States Patent and Trademark Office	9427413	August 30, 2016
	‌ US Patent 10793617 Methods of use of soluble CD24 for therapy of rheumatoid arthritis		OncoImmune	OncoImmune		United States Patent and Trademark Office	10793617	October 6, 2020
	‌ US Patent 8808697 Methods of use of soluble CD24 for therapy of rheumatoid arthritis	Patent 8808697 was granted and assigned to OncoImmune on August, 2014 by the United States Patent and Trademark Office.		OncoImmune		United States Patent and Trademark Office	8808697	August 19, 2014
	‌ US Patent 10799558 Use of CD24 proteins for treating leptin-deficient conditions		OncoImmune	OncoImmune		United States Patent and Trademark Office	10799558	October 13, 2020
	‌ US Patent 10618960 Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof			OncoImmune		United States Patent and Trademark Office	10618960	April 14, 2020

9 results

0 selected

9 results

0 selected